SCHEMBL12316620

SCHEMBL12316620

CC(C)Oc1cc2c(cc1Cl)C(=O)CCO2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
TSHR P16473 2/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MAOB P27338 9/20 0.41
MAOA P21397 1/20 0.41
CHEK1 O14757 1/20 0.40
GRM5 P41594 7/20 0.38
CSNK2A1 P68400 2/20 0.37
PPOX P50336 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
NPC1 O15118 1/20 0.36
NFKB1 P19838 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12316656 0.84 MAOB (0.42) ALDH1A1HPGDTSHRKDM4EMAOB
SCHEMBL30888618 0.84 MAOB (0.44) ALDH1A1HPGDTSHRKDM4EPOLB
SCHEMBL16334001 0.83 ACHE (0.50) ALDH1A1HPGDTSHRKDM4EHSD17B10
SCHEMBL13846725 0.83 MAOB (0.39) ALDH1A1HPGDMAOBMAOAGRM5
SCHEMBL1694551 0.78 MAOB (0.53) ALDH1A1HPGDMAOBMAOAGRM5
SCHEMBL12186154 0.78 MAOB (0.44) ALDH1A1HPGDMAOBMAOAGRM5
SCHEMBL12316638 0.76 CSNK2A1 (0.43) ALDH1A1HPGDMAOBMAOAGRM5
SCHEMBL12316537 0.76 TSHR (0.40) ALDH1A1HPGDTSHRKDM4EPOLB
SCHEMBL23778012 0.76 HTR1A (0.49) ALDH1A1HPGDMAOBCHEK1GRM5
SCHEMBL1985927 0.75 MAOB (0.47) ALDH1A1HPGDMAOBMAOAGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263592-B2 Equilibrative nucleoside transporter ENT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2012-09-11 US disclosed
US-8263592-B2 Equilibrative nucleoside transporter ENT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2012-09-11 US disclosed
US-20100280025-A1 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-11-04 US disclosed
US-20100280025-A1 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280025-A1 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS SLC29A1, SLC29A2, SLC43A3 ALDH1A1 516/4885HPGD 969/4885TSHR 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.